GFM-DACORAL-DLI: ASTX727 and donor lymphocyte infusions (DLI) after allogeneic stem cell transplantation (ALLO SCT) in very high-risk MDS or AML patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515353-24-00

Acronym

GFM-DACORAL-DLI

Enrollment

Registered

2024-10-18

Start date

2021-06-22

Completion date

2025-04-22

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with high risk myelodysplastic syndrome or acute myeloid leukemia

Brief summary

DFS at 1 year post transplant

Detailed description

Overall survival from the date of transplantation and from the date of inclusion at 1 year and 2 years, Risk factors for DFS, OS NRM at 1 year and 2 years

Interventions

DRUGASTX727

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
DFS at 1 year post transplant	—

Secondary

Measure	Time frame
Overall survival from the date of transplantation and from the date of inclusion at 1 year and 2 years, Risk factors for DFS, OS NRM at 1 year and 2 years	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026